{
    "Clinical Trial ID": "NCT00246571",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Sunitinib",
        "  SU011248 (Sutent [sunitinib malate, hereafter referred to as sunitinib]) oral capsules, 37.5 milligrams (mg) once daily (QD) in a continuous regimen, expressed in 3-week cycles. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity (DLT). Dose escalated to sunitinib 50 mg QD if minimal toxicities.",
        "INTERVENTION 2: ",
        "  Standard of Care",
        "  One of the following regimens was administered (at investigator's discretion): oral capecitabine 1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine 25-30 mg/m^2 rapid IV infusion or 60-80 mg/m^2 oral weekly, expressed in 3-week cycles; docetaxel 75-100 mg/m^2 via IV infusion every 3 weeks; paclitaxel 175-200 mg/m^2 via IV infusion every 3 weeks; paclitaxel 80-90 mg/m^2 weekly, in a continuous regimen expressed in 3-week cycles or 3 weeks of treatment followed by 1 week of rest; gemcitabine 800-1250 mg/m^2 via IV infusion, Days 1 and 8 every 3 weeks. If RECIST defined progression was met, participants could receive sunitinib, 37.5 mg oral capsules QD, in continuous 3-week cycles."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Recurrent or metastatic breast cancer",
        "  Estrogen receptor (ER), progestin receptor (PR) and HER2/neu receptor (HER2) negative status",
        "  Prior treatment with an anthracycline and a taxane in the adjuvant or advanced disease setting",
        "  Relapse following adjuvant chemotherapy within 6 months of last treatment and/or received one or two chemotherapy regimens for advanced disease",
        "Exclusion Criteria:",
        "  More than two chemotherapy regimens for advanced disease",
        "  Uncontrolled/symptomatic spread of cancer to the brain"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression-Free Survival (PFS)",
        "  Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause. PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was \"Death\").",
        "  Time frame: Baseline, every 6 weeks until disease progression or death (up to 3 years from first dose)",
        "Results 1: ",
        "  Arm/Group Title: Sunitinib",
        "  Arm/Group Description: SU011248 (Sutent [sunitinib malate, hereafter referred to as sunitinib]) oral capsules, 37.5 milligrams (mg) once daily (QD) in a continuous regimen, expressed in 3-week cycles. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity (DLT). Dose escalated to sunitinib 50 mg QD if minimal toxicities.",
        "  Overall Number of Participants Analyzed: 113",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  Core radiology laboratory assessment: 2.0        (1.5 to 2.8)",
        "  Investigator's assessment: 1.7        (1.5 to 2.6)",
        "Results 2: ",
        "  Arm/Group Title: Standard of Care",
        "  Arm/Group Description: One of the following regimens was administered (at investigator's discretion): oral capecitabine 1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine 25-30 mg/m^2 rapid IV infusion or 60-80 mg/m^2 oral weekly, expressed in 3-week cycles; docetaxel 75-100 mg/m^2 via IV infusion every 3 weeks; paclitaxel 175-200 mg/m^2 via IV infusion every 3 weeks; paclitaxel 80-90 mg/m^2 weekly, in a continuous regimen expressed in 3-week cycles or 3 weeks of treatment followed by 1 week of rest; gemcitabine 800-1250 mg/m^2 via IV infusion, Days 1 and 8 every 3 weeks. If RECIST defined progression was met, participants could receive sunitinib, 37.5 mg oral capsules QD, in continuous 3-week cycles.",
        "  Overall Number of Participants Analyzed: 104",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  Core radiology laboratory assessment: 2.7        (1.7 to 2.8)",
        "  Investigator's assessment: 2.5        (1.4 to 2.9)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 40/110 (36.36%)",
        "  Anaemia * 3/110 (2.73%)",
        "  Disseminated intravascular coagulation * 1/110 (0.91%)",
        "  Febrile neutropenia * 2/110 (1.82%)",
        "  Leukopenia * 0/110 (0.00%)",
        "  Pancytopenia * 1/110 (0.91%)",
        "  Thrombocytopenia * 2/110 (1.82%)",
        "  Atrial fibrillation * 1/110 (0.91%)",
        "  Cardiac arrest * 1/110 (0.91%)",
        "  Cardiac failure * 1/110 (0.91%)",
        "  Cardiopulmonary failure * 1/110 (0.91%)",
        "Adverse Events 2:",
        "  Total: 21/103 (20.39%)",
        "  Anaemia * 0/103 (0.00%)",
        "  Disseminated intravascular coagulation * 0/103 (0.00%)",
        "  Febrile neutropenia * 2/103 (1.94%)",
        "  Leukopenia * 1/103 (0.97%)",
        "  Pancytopenia * 0/103 (0.00%)",
        "  Thrombocytopenia * 0/103 (0.00%)",
        "  Atrial fibrillation * 1/103 (0.97%)",
        "  Cardiac arrest * 0/103 (0.00%)",
        "  Cardiac failure * 0/103 (0.00%)",
        "  Cardiopulmonary failure * 0/103 (0.00%)"
    ]
}